共查询到20条相似文献,搜索用时 31 毫秒
1.
Andreas Marc Palmer Sandra Chrismann Gabriela Münch Christof Brehm Peter Jan Zimmermann Wilm Buhr Jörg Senn-Bilfinger Martin Philipp Feth Wolfgang Alexander Simon 《Bioorganic & medicinal chemistry》2009,17(1):368-384
Asymmetric and symmetric spiro(imidazo[1,2-a]pyrano[2,3-c]pyridine-9-indenes) were prepared using a synthetic approach that comprised a cross-metathesis reaction and an acid-catalyzed cycloisomerisation as key steps. The target compounds constitute potent inhibitors of the gastric proton pump enzyme with inhibitory activity comparable to potassium-competitive acid blockers (P-CABs) belonging to the known 9-aryl-7H-8,9-dihydropyrano[2,3-c]imidazo[1,2-a]pyridine series. Spiro(imidazo[1,2-a]pyrano[2,3-c]pyridine-9,2′-indenes) represent the first example for P-CABs, in which the distance between the heterocyclic scaffold and the aryl residue has been modified, and are promising candidates for further development as anti-ulcer drugs. 相似文献
2.
Zhaoyang Meng Jeffrey P. Ciavarri Andrew McRiner Yinyan Zhao Lianyun Zhao Panduranga Adulla Reddy Xingmin Zhang Thierry O. Fischmann Charles Whitehurst M. Arshad Siddiqui 《Bioorganic & medicinal chemistry letters》2013,23(10):2863-2867
Chemistry has been developed to access both imidazo[1,2-a]pyrazines and imidazo[1,2-c]pyrimidines. Small structural modifications in both series led to a switch of potency between two kinases involved in mediating cell cycle checkpoint control, CHK1 and MK2. 相似文献
3.
Thomas P. Matthews Tatiana McHardy Suki Klair Kathy Boxall Martin Fisher Michael Cherry Charlotte E. Allen Glynn J. Addison John Ellard G. Wynne Aherne Isaac M. Westwood Rob van Montfort Michelle D. Garrett John C. Reader Ian Collins 《Bioorganic & medicinal chemistry letters》2010,20(14):4045-4049
A range of 3,6-di(hetero)arylimidazo[1,2-a]pyrazine ATP-competitive inhibitors of CHK1 were developed by scaffold hopping from a weakly active screening hit. Efficient synthetic routes for parallel synthesis were developed to prepare analogues with improved potency and ligand efficiency against CHK1. Kinase profiling showed that the imidazo[1,2-a]pyrazines could inhibit other kinases, including CHK2 and ABL, with equivalent or better potency depending on the pendant substitution. These 3,6-di(hetero)aryl imidazo[1,2-a]pyrazines appear to represent a general kinase inhibitor scaffold. 相似文献
4.
Buckmelter AJ Ren L Laird ER Rast B Miknis G Wenglowsky S Schlachter S Welch M Tarlton E Grina J Lyssikatos J Brandhuber BJ Morales T Randolph N Vigers G Martinson M Callejo M 《Bioorganic & medicinal chemistry letters》2011,21(4):1248-1252
Virtual and high-throughput screening identified imidazo[1,2-a]pyrazines as inhibitors of B-Raf. We describe the rationale, SAR, and evolution of the initial hits to a series of furo[2,3-c]pyridine indanone oximes as highly potent and selective inhibitors of B-Raf. 相似文献
5.
Aaron Smith Zhi-Jie Ni Daniel Poon Zilin Huang Zheng Chen Qiong Zhang Laura Tandeske Hanne Merritt Kevin Shoemaker John Chan Susan Kaufman Kay Huh Jeremy Murray Brent A. Appleton Sandra W. Cowan-Jacob Clemens Scheufler Takanori Kanazawa Johanna M. Jansen Cynthia M. Shafer 《Bioorganic & medicinal chemistry letters》2017,27(23):5221-5224
A series of imidazo[1,2-a]pyridin-6-yl-benzamide analogs was designed as inhibitors of B-RAFV600E. Medicinal chemistry techniques were employed to explore the SAR for this series and improve selectivity versus P38 and VEGFR2. 相似文献
6.
Yuya Oguro Douglas R. Cary Naoki Miyamoto Michiko Tawada Hidehisa Iwata Hiroshi Miki Akira Hori Shinichi Imamura 《Bioorganic & medicinal chemistry》2013,21(15):4714-4729
For the purpose of discovering novel type-II inhibitors of vascular endothelial growth factor receptor 2 (VEGFR2) kinase, we designed and synthesized 5,6-fused heterocyclic compounds bearing a anilide group. A co-crystal structure analysis of imidazo[1,2-b]pyridazine derivative 2 with VEGFR2 revealed that the N1-nitrogen of imidazo[1,2-b]pyridazine core interacts with the backbone NH group of Cys919. To retain this essential interaction, we designed a series of imidazo[1,2-a]pyridine, [1,2,4]triazolo[1,5-a]pyridine, thiazolo[5,4-b]pyridine, and 1,3-benzothiazole derivatives maintaining a ring nitrogen as hydrogen bond acceptor (HBA) at the corresponding position. All compounds thus designed displayed strong inhibitory activity against VEGFR2 kinase, and the [1,2,4]triazolo[1,5-a]pyridine 13d displayed favorable physicochemical properties. Furthermore, 13d inhibited VEGFR2 kinase with slow dissociation kinetics and also inhibited platelet-derived growth factor receptor (PDGFR) kinases. Oral administration of 13d showed potent anti-tumor efficacy in DU145 and A549 xenograft models in nude mice. 相似文献
7.
Hiroyuki Kishino Minoru Moriya Shunji Sakuraba Toshihiro Sakamoto Hidekazu Takahashi Takao Suzuki Ryuichi Moriya Masahiko Ito Hisashi Iwaasa Norihiro Takenaga Akane Ishihara Akio Kanatani Nagaaki Sato Takehiro Fukami 《Bioorganic & medicinal chemistry letters》2009,19(16):4589-4593
A series of imidazo[1,2-a]pyridine derivatives was identified and evaluated for MCH1R binding and antagonistic activity. Introduction of a methyl substituent at the 3-position of imidazo[1,2-a]pyridine provided compounds with a significant improvement in MCH1R affinity. Representative compounds in this series exhibited good potency and brain exposure in rats. 相似文献
8.
David B. Belanger Patrick J. Curran Alan Hruza Johannes Voigt Zhaoyang Meng Amit K. Mandal M. Arshad Siddiqui Andrea D. Basso Kimberly Gray 《Bioorganic & medicinal chemistry letters》2010,20(17):5170-5174
The synthesis and structure–activity relationships (SAR) of novel, potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors are described. The X-ray crystal structure of imidazo[1,2-a]pyrazine Aurora inhibitor 1j is disclosed. Compound 10i was identified as lead compound with a promising overall profile. 相似文献
9.
David B. Belanger Michael J. Williams Patrick J. Curran Amit K. Mandal Zhaoyang Meng Matthew P. Rainka Tao Yu Neng-Yang Shih M. Arshad Siddiqui Ming Liu Seema Tevar Suining Lee Lianzhu Liang Kimberly Gray Bohdan Yaremko Jennifer Jones Elizabeth B. Smith Dan B. Prelusky Andrea D. Basso 《Bioorganic & medicinal chemistry letters》2010,20(22):6739-6743
We report a series of potent imidazo[1,2-a]pyrazine-based Aurora kinase inhibitors. Optimization of the solvent accessible 8-position led to improvements in both oral bioavailability and off-target kinase inhibition. Compound 25 demonstrates anti-tumor activity in an A2780 ovarian tumor xenograft model. 相似文献
10.
《Bioorganic & medicinal chemistry》2014,22(4):1303-1312
Chromosomal translocations involving anaplastic lymphoma kinase (ALK) are the driving mutations for a range of cancers and ALK is thus considered an attractive therapeutic target. We synthesized a series of functionalized benzo[4,5]imidazo[1,2-c]pyrimidines and benzo[4,5]imidazo[1,2-a]pyrazines by an aza-Graebe–Ullman reaction, followed by palladium-catalyzed cross-coupling reactions. A sequential regioselective cross-coupling route is reported for the synthesis of unsymmetrically disubstituted benzo[4,5]imidazo[1,2-a]pyrazines. The inhibition of ALK was evaluated and compound 19 in particular showed good activity against both the wild type and crizotinib-resistant L1196M mutant in vitro and in ALK-transfected BaF3 cells. 相似文献
11.
Nathalie Bouloc Jonathan M. Large Magda Kosmopoulou Chongbo Sun Amir Faisal Mizio Matteucci Jóhannes Reynisson Nathan Brown Butrus Atrash Julian Blagg Edward McDonald Spiros Linardopoulos Richard Bayliss Vassilios Bavetsias 《Bioorganic & medicinal chemistry letters》2010,20(20):5988-5993
Co-crystallisation of the imidazo[1,2-a]pyrazine derivative 15 (3-chloro-N-(4-morpholinophenyl)-6-(pyridin-3-yl)imidazo[1,2-a]pyrazin-8-amine) with Aurora-A provided an insight into the interactions of this class of compound with Aurora kinases. This led to the design and synthesis of potent Aurora-A inhibitors demonstrating up to 70-fold selectivity in cell-based Aurora kinase pharmacodynamic biomarker assays. 相似文献
12.
Hiroki Shimizu Shinji Tanaka Tadashi Toki Isao Yasumatsu Toshihiko Akimoto Kaoru Morishita Tomonori Yamasaki Takanori Yasukochi Shin Iimura 《Bioorganic & medicinal chemistry letters》2010,20(17):5113-5118
Imidazo[1,2-b]pyridazine derivatives from high-throughput screening were developed as IKKβ inhibitors. By the optimization of the 3- and 6-position of imidazo[1,2-b]pyridazine scaffold, cell-free IKKβ inhibitory activity and TNFα inhibitory activity in THP-1 cell increased. Also, these compounds showed high kinase selectivity. The structure–activity relationship was revealed and the interaction model of imidazo[1,2-b]pyridazine compounds with IKKβ was constructed. 相似文献
13.
Chemical–Genetic Profiling of Imidazo[1,2-a]pyridines and -Pyrimidines Reveals Target Pathways Conserved between Yeast and Human Cells
下载免费PDF全文
![点击此处可从《PLoS genetics》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Lisa Yu Andres Lopez Abderrahmane Anaflous Brahim El Bali Abdellah Hamal Elke Ericson Lawrence E. Heisler Angus McQuibban Guri Giaever Corey Nislow Charles Boone Grant W. Brown Mohammed Bellaoui 《PLoS genetics》2008,4(11)
Small molecules have been shown to be potent and selective probes to understand cell physiology. Here, we show that imidazo[1,2-a]pyridines and imidazo[1,2-a]pyrimidines compose a class of compounds that target essential, conserved cellular processes. Using validated chemogenomic assays in Saccharomyces cerevisiae, we discovered that two closely related compounds, an imidazo[1,2-a]pyridine and -pyrimidine that differ by a single atom, have distinctly different mechanisms of action in vivo. 2-phenyl-3-nitroso-imidazo[1,2-a]pyridine was toxic to yeast strains with defects in electron transport and mitochondrial functions and caused mitochondrial fragmentation, suggesting that compound 13 acts by disrupting mitochondria. By contrast, 2-phenyl-3-nitroso-imidazo[1,2-a]pyrimidine acted as a DNA poison, causing damage to the nuclear DNA and inducing mutagenesis. We compared compound 15 to known chemotherapeutics and found resistance required intact DNA repair pathways. Thus, subtle changes in the structure of imidazo-pyridines and -pyrimidines dramatically alter both the intracellular targeting of these compounds and their effects in vivo. Of particular interest, these different modes of action were evident in experiments on human cells, suggesting that chemical–genetic profiles obtained in yeast are recapitulated in cultured cells, indicating that our observations in yeast can: (1) be leveraged to determine mechanism of action in mammalian cells and (2) suggest novel structure–activity relationships. 相似文献
14.
A. A. Spasov D. S. Yakovlev D. V. Maltsev O. N. Zhukovskaya V. A. Anisimova G. I. Kovalev I. A. Zimin Y. V. Morkovina 《Russian Journal of Bioorganic Chemistry》2016,42(4):397-403
We studied in vitro the 5-HT2A antagonistic activity of 16 imidazo[1,2-a]benzimidazole derivatives. Using the radioligand method we showed the binding of 9-(2-diethylaminoethyl)-2-(4-methoxyphenyl)imidazo[1,2-a]benzimidazol dinitrate to the 2A subtype serotonin receptor. 相似文献
15.
《Bioorganic & medicinal chemistry letters》2020,30(18):127418
The activin-like kinases are a family of kinases that play important roles in a variety of disease states. Of this class of kinases, ALK2, has been shown by a gain-of-function to be the primary driver of the childhood skeletal disease fibrodysplasia ossificans progressiva (FOP) and more recently the pediatric cancer diffuse intrinsic pontine glioma (DIPG). Herein, we report our efforts to identify a novel imidazo[1,2-a]pyridine scaffold as potent inhibitors of ALK2 with good in vivo pharmacokinetic properties suitable for future animal studies. 相似文献
16.
Nick Bailey Mark J. Bamford Delphine Brissy Joanna Brookfield Emmanuel Demont Richard Elliott Neil Garton Irene Farre-Gutierrez Thomas Hayhow Gail Hutley Antoinette Naylor Terry A. Panchal Hui-Xian Seow David Spalding Andrew K. Takle 《Bioorganic & medicinal chemistry letters》2009,19(13):3602-3606
Acid pump antagonists (APAs) such as the imidazo[1,2-a]pyridine AZD-0865 2 have proven efficacious at low oral doses in acid related gastric disorders. Herein we describe some of the broader SAR in this class of molecule and detail the discovery of an imidazo[1,2-a]pyridine 15 which has excellent efficacy in animal models of gastric acid secretion following oral administration, as well as a good overall developability profile. The discovery strategy focuses on use of heteroaryl and heterocyclic substituents at the C-6 position and optimization of developability characteristics through modulation of global physico-chemical properties. 相似文献
17.
This letter describes two unprecedented one-pot high yielding synthetic approaches to imidazo[1,2-a]pyridine scaffolds from carbohydrates. The first approach involves microwave-assisted acid-catalyzed domino reactions of unprotected d-glucose/d-xylose with ammonium acetate and benzoin to afford polyhydroxy iminosugar-bearing tetrahydroimidazo[1,2-a]pyridines. In the second approach, polyhydroxy iminosugar-bearing tetrahydrobenzimidazo[1,2-a]pyridines were synthesized by using unprotected d-glucose/d-xylose and 1,2-diamines in the presence of 10 mol % of oxalic acid under solvent-free microwave irradiation conditions. 相似文献
18.
Naoki Miyamoto Yuya Oguro Terufumi Takagi Hidehisa Iwata Hiroshi Miki Akira Hori Shinichi Imamura 《Bioorganic & medicinal chemistry》2012,20(24):7051-7058
The vascular endothelial growth factor (VEGF) signaling pathway has been implicated in tumor angiogenesis, and inhibition of the VEGF pathway is considered an efficacious method for treating cancer. Herein, we describe synthetic studies of imidazo[1,2-b]pyridazine derivatives as VEGF receptor 2 (VEGFR2) kinase inhibitors. The imidazo[1,2-b]pyridazine scaffold was designed and synthesized as a hinge binder according to the previously reported crystal structure of pyrrolo[3,2-d]pyrimidine 1 with VEGFR2. Structure–activity relationship studies revealed that meta-substituted 6-phenoxy-imidazo[1,2-b]pyridazine derivatives had potent affinity for VEGFR2. In particular, N-[3-(imidazo[1,2-b]pyridazin-6-yloxy)phenyl]-3-(trifluoromethyl)benzamide (6b) exhibited strong inhibitory activity against VEGFR2 with an IC50 value of 7.1 nM, and it inhibited platelet-derived growth factor receptor β kinase with an IC50 value of 15 nM. 相似文献
19.
《Bioorganic & medicinal chemistry letters》2014,24(15):3493-3498
A set of 5,6-fused bicyclic heteroaromatic scaffolds were investigated for their in vitro anti-tubercular activity versus replicating and non-replicating strains of Mycobacterium tuberculosis (Mtb) in an attempt to find an alternative scaffold to the imidazo[1,2-a]pyridine and imidazo[1,2-a]pyrimidines that were previously shown to have potent activity against replicating and drug resistant Mtb. The five new bicyclic heteroaromatic scaffolds explored in this study include a 2,6-dimethylimidazo[1,2-b]pyridazine-3-carboxamide (7), a 2,6-dimethyl-1H-indole-3-carboxamide (8), a 6-methyl-1H-indazole-3-carboxamide (9), a 7-methyl-[1,2,4]triazolo[4,3-a]pyridine-3-carboxamide (10), and a 5,7-dimethyl-[1,2,4]triazolo[1,5-a]pyrimidine-2-carboxamide (11). Additionally, imidazo[1,2-a]pyridines isomers (2 and 12) and a homologous imidazo[1,2-a]pyrimidine isomer (6) were prepared and compared. Compounds 2 and 6 were found to be the most potent against H37Rv Mtb (MIC’s of 0.1 μM and 1.3 μM) and were inactive (MIC >128 μM) against Staphylococcus aureus, Escherichia coli and Candida albicans. Against other non-tubercular mycobacteria strains, compounds 2 and 6 had activity against Mycobacterium avium (16 and 122 μM, respectively), Mycobacterium kansasii (4 and 19 μM, respectively), Mycobacterium bovis BCG (1 and 8 μM, respectively) while all the other scaffolds were inactive (>128 μM). 相似文献
20.
Robert R. Singhaus Ronald C. Bernotas Robert Steffan Edward Matelan Elaine Quinet Ponnal Nambi Irene Feingold Christine Huselton Anna Wilhelmsson Annika Goos-Nilsson Jay Wrobel 《Bioorganic & medicinal chemistry letters》2010,20(2):521-525
Replacement of a quinoline with an imidazo[1,2-a]pyridine in a series of liver X receptor (LXR) agonists incorporating a [3-(sulfonyl)aryloxyphenyl] side chain provided high affinity LXR ligands 7. In functional assays of LXR activity, good agonist potency and efficacy were found for several analogs. 相似文献